Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 25 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Oveporexton (Primary)
Indications Cataplexy; Narcolepsy
Focus Registrational; Therapeutic Use
Acronyms FirstLight
Sponsors Takeda

Most Recent Events

14 Jul 2025 According to the Takeda media release, the company plans to submit NDA to the USFDA and additional global regulatory authorities in fiscal year 2025.
14 Jul 2025 According to the Takeda media release, the company intends to present the positive results from this study at upcoming medical congresses.
14 Jul 2025 Results presented in the Takeda Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com